Calcium, Vitamin D & the Drug Tier

The supplement aisle promises to fix bones in a capsule; the evidence says the answer is mostly food, and when food is not enough the next step is not a bigger bottle but a different tier entirely. This page sorts the stack in order of honesty: what diet can do, what the vitamin D and calcium trials actually found, and when medication becomes the answer.

Calcium: The Raw-Material Problem

The skeleton holds about 99% of the body's calcium — roughly a kilogram of it — and blood calcium is defended ferociously, because nerves and muscle need it in a tight range. When dietary calcium runs short, parathyroid hormone rises and orders the remodeling crews to release calcium from bone. Chronic shortfall, in other words, is a slow raid on the ledger the first page in this series describes. The intake target that keeps the raid off is 1,000 mg a day for women under 50 and 1,200 mg a day after 50 (Institute of Medicine, Dietary Reference Intakes, 2011). The word "intake" does the work here: the target is a food target, and the trial evidence repeatedly failed to find that reaching it by pill helps — a point the parent topic's calcium callout owns in detail.

Where the Calcium Lives

Three servings of dairy — or fortified equivalents — lands most women at the target without arithmetic. Approximate amounts, from standard food composition data:

Spinach earns its verdict honestly: its oxalate binds calcium so tightly that only a small fraction is absorbed — a reminder that the label number and the absorbed number are different quantities. Leafy greens are superb foods; they are simply not a calcium strategy on their own.

Vitamin D: The Absorption Cofactor

Vitamin D is what lets the gut absorb calcium efficiently — a genuine deficiency (<20 ng/mL by the Endocrine Society's convention) is worth correcting, and correction clearly helps the deficient. The recommended intake is 600 IU a day to age 70 and 800 IU after (Institute of Medicine, 2011). Where the evidence gets honest is above that floor: in the VITAL trial, 2,000 IU daily in over 25,000 midlife and older adults did not reduce fractures (LeBoff et al., New England Journal of Medicine, 2022), and a large Australian trial of monthly high-dose vitamin D reached the same null (Neale et al., Lancet Diabetes & Endocrinology, 2022). One caution even underlines the point: an annual megadose of 500,000 IU actually increased falls and fractures in one trial (Sanders et al., JAMA, 2010). The policy follows: test when risk factors warrant it, correct a deficiency, and skip the megadose theater. An older finding survives as the one nuance — combined calcium plus vitamin D appeared to reduce hip fractures in frail, institutionalized older adults who were commonly deficient — which is a story about treating deficiency in the most at-risk, not about routine supplementation for everyone else.

The Supplement Honesty, In One Paragraph

The meta-analytic bottom line has been stable for nearly a decade: calcium or vitamin D supplements have not been associated with fewer fractures in community-dwelling adults (Zhao et al., JAMA, 2017), a systematic review found that raising calcium intake by food or pill does not reduce fracture risk (Bolland et al., BMJ, 2015), and a possible small cardiovascular signal with calcium supplements reported in some meta-analyses remains debated rather than settled. None of this makes supplements dangerous for someone closing a measured gap; it makes them what the parent topic says: gap-fillers, not insurance. The skeleton's better friends are on the plate and in the gym — the two pages immediately behind this one.

When Medication Becomes the Answer

Medication enters when the ten-year arithmetic from the Fracture Math page crosses a line, not when a supplement bottle runs out. In practice, treatment is generally indicated when any of these is true: a hip or vertebral fracture has already occurred (the strongest indication of all — the imminent risk window is real), the T-score is −2.5 or below, or the FRAX probability reaches about 20% for major osteoporotic fracture or 3% for hip (US National Osteoporosis Foundation thresholds). Within that group, the medications are among the better-proven treatments in all of chronic-disease medicine — the chart shows the vertebral-fracture results from the pivotal trials:

The Drug Classes, Tier by Tier

Four classes carry the modern conversation. They differ in mechanism, schedule, and where they sit in a treatment sequence:

Two notes complete the picture. Bisphosphonates sit first because they are effective, cheap, and long-studied; the anabolic agents are usually reserved for the highest-risk patients or when first-line treatment stalls. And hormone therapy, covered honestly by the WHI-corrected topic, genuinely preserves bone — but it is chosen for the whole woman at the right window, not prescribed for bone alone. None of the tiers above is a do-it-yourself shelf; the next section is the fine print.

The Fine Print: Holidays, Rebound, and Rare Harms

Osteoporosis therapy is a sequence managed over years, not a course you finish — and the sequencing rules are where damage is most often done:

• ⏸️ Bisphosphonate holidays are real. After three to five years, if risk has dropped, a planned pause is standard — the drug lingers in bone and protection persists for a while. This is a clinician's call, timed to the risk, not a self-directed experiment.
• 🚫 Denosumab has no holiday. Stopping it without follow-on therapy causes rapid rebound bone loss and an increased risk of vertebral fractures — the transition off is planned from the start, and it is the clearest "never stop on your own" rule in this tier.
• 🦵 The rare harms are rare and worth knowing. Osteonecrosis of the jaw is uncommon at osteoporosis doses, and atypical thigh-bone fractures appear at low rates with long-term use — new thigh or groin pain on treatment is a report-it symptom.
• 🧭 Sequencing beats loyalty. Current practice often builds first with an anabolic and holds with an anti-resorptive — a planned handoff that is, again, clinician territory through and through.

Questions, Answered Briefly

• 🥛 Should I be taking a calcium pill "just in case"? No — the trials say insurance calcium doesn't prevent fractures. Close a measured food gap, and only then consider a small supplement.
• ☀️ What about vitamin D — should everyone take it? Test if you're at risk; correct if deficient. Above the floor, the large trials found no fracture benefit from routine dosing.
• 💊 My T-score is −2.6 — do I automatically need medication? Not automatically. The number opens the conversation; your age, fracture history, and ten-year probability decide it — with a clinician.
• ⏳ If I start a bisphosphonate, am I on it for life? Usually not — holidays after three to five years are standard practice when risk allows, decided by the same clinician who started it.
• 🧱 What should I do alongside any medication? The identical stack — load, protein, food-first calcium, and fall prevention. The drugs tilt the ledger; the lifestyle keeps the body that has to live with it.

Related Topics